ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,738.17
-0.13%
Dow Jones
42,313.00
0.33%
US Dollar vs MXN
19.70102
0.28%
Brent Oil
72.275
0.79%
Bitcoin
64,501.39
-1.72%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
30/09/202400:30Alliance NewsAlliance NewsGET READY: Bango, Frenkel, Playtech, and Spectra at 0700 BST
30/09/202400:30Alliance NewsAlliance NewsAlliance News UK - start of day
30/09/202400:30Business WireAFYREN Announces Its 2024 Half-Year Financial ResultsEU:ALAFYAfyren
30/09/202400:30Business WirePoxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 millionEU:POXELPoxel
30/09/202400:30Business WireTheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary FibrosisEU:ALVETTheraVet SA
30/09/202400:30Business WireAFYREN annonce ses résultats financiers semestriels 2024EU:ALAFYAfyren
30/09/202400:30Business WireTheraVet annonce un projet de transformation stratégique en vue de créer un leader de la fibrose pulmonaire idiopathique humaineEU:ALVETTheraVet SA
30/09/202400:30Business WirePoxel annonce un accord avec OrbiMed pour monétiser une partie des redevances issues des ventes de TWYMEEG® à hauteur de 50 millions de dollarsEU:POXELPoxel
30/09/202400:22PR Newswire (US)World's First Carbon Neutral Salad: The Revolutionary Drinkable Salad that's Good for You and the Planet
30/09/202400:21PR Newswire (US)Persistent Advances Data Privacy and AI-Driven Business Transformation with the Acquisition of Arrka
30/09/202400:06PR Newswire (US)HSL CHAIRS : EXPERT REVEALS SITTING IN CORRECT SIZE CHAIR REDUCES BLOOD PRESSURE
30/09/202400:06PR Newswire (US)C-Crete Technologies Pours World's First Granite-Based Concrete - Free of Portland Cement and CO2 Emissions - at Manhattan Supertall Building
30/09/202400:00Business WireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024NASDAQ:IPHAInnate Pharma SA
30/09/202400:00Business WireAu FlowFest 2024, Forrester présentera un aperçu des tendances en matière d’automatisation et d’IA et évoquera l’avenir de l’orchestration des processus
30/09/202400:00Business WireCARMAT Announces the Completion of Its Capital Increase for a Gross Amount of €10.3 Million (Namely 100% of the Initial Offer)EU:ALCARCarmat
30/09/202400:00Business WireGeNeuro SA Obtains the Opening of Debt-Restructuring ProceedingsEU:GNROGeNeuro SA
30/09/202400:00Business WireInnate Pharma co-organise un symposium scientifique en présence d’experts de l’Immunotherapie à New York le 3 octobre 2024NASDAQ:IPHAInnate Pharma SA
30/09/202400:00Business WireGeNeuro SA obtient l’ouverture d’une procédure de sursis concordataireEU:GNROGeNeuro SA
30/09/202400:00Business WireValerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics CompanyEU:ALVIOValerio Therapeutics
30/09/202400:00GlobeNewswire Inc.Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:ADXNAddex Therapeutics Ltd
30/09/202400:00Business WireValerio Therapeutics acquiert Emglev Therapeutics, une société spécialisée dans les thérapies à base d'anticorps à domaine uniqueEU:ALVIOValerio Therapeutics
30/09/202400:00Business WireForrester to Present at FlowFest’24: Insights on Automation Trends, AI, and the Future of Business Orchestration
30/09/202400:00Business WireForrester präsentiert auf dem FlowFest'24: Einblicke in Automatisierungstrends, KI und die Zukunft der Unternehmensorchestrierung
30/09/202400:00Business WireCARMAT annonce la réalisation à 100% de son augmentation de capital d’un montant brut de 10,3 M€EU:ALCARCarmat
30/09/202400:00PR Newswire (US)Probiotical S.p.A. defines, accelerates, and leverages digital transformation to meet growing demandNYSE:ROKRockwell Automation Inc
30/09/202400:00PR Newswire (US)Build-A-Bear Celebrates the Month of "OctoBEAR" with Second Wave of Halloween CollectiblesNYSE:BBWBuild A Bear Workshop Inc
30/09/202400:00PR Newswire (US)Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer
30/09/202400:00PR Newswire (US)Matrixport Expands Footprint in Europe with Acquisition of Swiss-based Crypto Finance Asset Management
29/09/202423:50PR Newswire (US)India's luxury beauty market presents massive growth potential amid unique challenges, finds report by Kearney and LUXASIA
29/09/202423:40Business WireFLIR Introduces TrafiBot Dual AI Camera to Enhance Interurban Traffic Flow and Road Safety

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
FX
EURMXN
Euro vs MXN
COIN
ETHUSD
Ethereum
SPI
SP500
S&P 500
NASDAQ
AMZN
Amazon.com
USOTC
ADDYY
Adidas (QX)
NASDAQ
GOOGL
Alphabet
FX
USDMXN
US Dollar vs MXN
COIN
BTCUSD
Bitcoin
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
ADAUSD
Cardano
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
MSFT
Microsoft
CCOM
US500
US 500
NYSE
BAC
Bank of America
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados